Meadowsweet

Metadata

Approved Indications

Commission E

• No monograph — Meadowsweet was not positively assessed by the German Commission E
• A negative monograph was issued, indicating that Commission E found the evidence insufficient at the time of assessment

ESCOP

• No monograph — Not included in ESCOP monograph collection

EMA/HMPC

• Traditional use: Herbal medicinal product for the supportive treatment of common cold
• Traditional use: Herbal medicinal product as adjuvant in the relief of minor joint pain
• Based on long-standing traditional use (at least 30 years, including 15 years within the EU)

Agreement/Disagreement Between Bodies

The regulatory picture for meadowsweet is weak. Commission E issued a negative monograph, ESCOP has not assessed it, and only EMA/HMPC has issued a traditional use monograph — the lowest tier of regulatory recognition. This contrasts sharply with willow bark (also a salicylate-containing herb), which holds positive monographs from all three bodies. The discrepancy likely reflects the absence of clinical trial data for meadowsweet, whereas willow bark has been studied in multiple RCTs. Despite sharing salicylate chemistry, the two herbs have very different evidence profiles.

Conditions Treated

Primary

• Supportive treatment of common cold (EMA traditional use)
• Mild joint pain — adjuvant (EMA traditional use)

Secondary

• Mild gastrointestinal discomfort (traditional, not formally approved)
• Feverish conditions (traditional diaphoretic use)

Traditional/Historical

• Dyspepsia and gastric hyperacidity (traditional — notable given salicylate content)
• Diarrhea in children (historical, attributed to tannin content)
• Urinary complaints (mild diuretic)
• Rheumatic complaints (longstanding European folk use)
• Meadowsweet was one of the three most sacred herbs of the Druids and has deep roots in Celtic and Anglo-Saxon herbalism

Mechanism of Action

Key Active Constituents

• Salicylaldehyde and methyl salicylate: Volatile compounds responsible for characteristic scent; released from glycosidic precursors (monotropitin, spiraein) upon hydrolysis
• Salicin: Present but in lower concentrations than in willow bark
• Flavonoids: Spiraeoside (quercetin-4’-glucoside, unique to meadowsweet), rutin, hyperoside, avicularin
• Tannins: Rugosins (ellagitannins, especially rugosin D) — contribute to astringent and gastroprotective effects
• Mucilage: Contributes to mucosal protection
• Phenolic acids: Salicylic acid, caffeic acid

Proposed Mechanisms

1. Anti-inflammatory Activity

   • Salicylate derivatives provide mild COX inhibition (similar to but weaker than willow bark)
   • Salicylic acid is a weak, reversible COX inhibitor — does NOT acetylate COX like aspirin
   • Flavonoids (particularly spiraeoside and rutin) contribute additional anti-inflammatory effects through inhibition of NF-kB and pro-inflammatory cytokines
   • Rugosin D demonstrates anti-complement activity in vitro

2. Analgesic Effect

   • Mild pain relief attributed to salicylate content and flavonoid anti-inflammatory synergy
   • Onset is slower than synthetic analgesics; more suited to chronic mild pain

3. Gastroprotective Effect (Paradoxical)

   • Despite containing salicylates (which as aspirin cause gastric irritation), meadowsweet is traditionally considered gastroprotective
   • This paradox is attributed to the tannins (rugosins) and mucilage, which form a protective layer on the gastric mucosa
   • The salicylate content in meadowsweet is substantially lower than pharmacological aspirin doses
   • Animal studies (Barnaulov & Denisenko, 1980) showed meadowsweet extract reduced ulcer formation in a stress-ulcer model

4. Diaphoretic Effect

   • Promotes perspiration, contributing to fever reduction
   • Traditional use in hot infusion for feverish colds (similar to elderflower and linden flower)

5. Antimicrobial Activity

   • In vitro activity against Helicobacter pylori reported (Cwikla et al., 2010)
   • Tannins and phenolic compounds contribute
   • Clinical significance is uncertain

Pharmacokinetics

• Salicylate glycosides (monotropitin, spiraein) are hydrolyzed in the gut, releasing salicylaldehyde and methyl salicylate
• These are further metabolized to salicylic acid in the liver
• The salicylate load from therapeutic doses of meadowsweet is substantially lower than from willow bark or aspirin

Clinical Evidence Summary

Meadowsweet Monotherapy

• No published randomized controlled trials for meadowsweet monotherapy have been identified
• The EMA traditional use monograph is based entirely on long-standing traditional use and pharmacological plausibility
• The Commission E negative monograph reflects this evidence gap

Preclinical Evidence

• Anti-inflammatory: Meadowsweet extract showed anti-inflammatory activity in carrageenan-induced paw edema model (animal)
• Gastroprotective: Barnaulov & Denisenko (1980) demonstrated dose-dependent gastroprotective effects in rat stress ulcer model
• Anti-Helicobacter pylori: Cwikla et al. (2010) reported in vitro activity of meadowsweet extract against H. pylori strains, including clarithromycin-resistant strains
• Antioxidant: High antioxidant capacity attributed to flavonoids and ellagitannins (in vitro)

Evidence in Context

• Meadowsweet’s evidence profile is far weaker than willow bark’s, despite shared salicylate chemistry
• Willow bark has multiple RCTs and EMA “well-established use” status for low back pain; meadowsweet has only traditional use status
• The traditional gastroprotective claim is pharmacologically plausible but not clinically proven
• Evidence rating E is appropriate: traditional use only, with no modern clinical substantiation

European vs. US/Anglophone Consensus

Safety Profile

Contraindications

• Aspirin/salicylate sensitivity or allergy: Contraindicated due to salicylate content (though cross-reactivity is theoretical and not confirmed)
• Active peptic ulcer disease: Caution despite traditional gastroprotective claim; salicylate content warrants avoidance
• Children and adolescents with viral infections: Theoretical Reye syndrome risk by analogy with aspirin (no reported cases with meadowsweet)
• Known hypersensitivity to Filipendula ulmaria or other Rosaceae family members

Drug Interactions

• NSAIDs: Additive anti-inflammatory and potential GI effects due to salicylate content
• Anticoagulants (warfarin, heparin): Theoretical additive anticoagulant effect via salicylate-mediated effects; monitor INR
• Antiplatelet drugs (aspirin, clopidogrel): Theoretical additive risk, though meadowsweet’s antiplatelet effect is likely minimal at therapeutic doses
• Methotrexate: Salicylates may reduce renal clearance; theoretical interaction
• Note: Actual clinical drug interaction reports with meadowsweet are absent from the literature; interactions are inferred from salicylate content

Side Effects

• Rare: Mild GI discomfort (nausea, stomach upset)
• Rare: Allergic reactions in individuals sensitive to salicylates
• Overall: Very well-tolerated at recommended doses; adverse event reports are extremely rare in the literature

Pregnancy/Lactation

• Pregnancy: Not recommended. Salicylate content raises theoretical concerns (premature closure of ductus arteriosus, bleeding risk). EMA does not recommend use during pregnancy. No reproductive toxicity data available.
• Lactation: Not recommended due to insufficient safety data and theoretical salicylate transfer to breast milk

Clinical Dosage

Recommended Forms and Doses

Duration of Treatment

• For common cold: 1-2 weeks (self-limiting condition)
• For mild joint pain: 2-4 weeks initially; consult a physician if symptoms persist
• Long-term use has not been evaluated in clinical studies

Preparation Note

• Traditional infusion is preferred over decoction, as prolonged boiling may degrade volatile salicylate compounds
• The flowers are considered more active than the herb (stems and leaves), but both are used

Sources

• EMA/HMPC. Community herbal monograph on Filipendula ulmaria (L.) Maxim., herba. European Medicines Agency, 2011.
• EMA/HMPC. Assessment report on Filipendula ulmaria (L.) Maxim., herba. European Medicines Agency.
• Barnaulov OD, Denisenko PP. Anti-ulcer action of the decoction of flowers of Filipendula ulmaria. Farmakol Toksikol. 1980;43(6):700-705.
• Cwikla C et al. Investigations into the antibacterial activities of phytotherapeutics against Helicobacter pylori and Campylobacter jejuni. Phytother Res. 2010;24(5):649-656.
• Halkes SBA et al. A structure/activity approach of the anti-complement activity of Filipendula ulmaria constituents. Biol Pharm Bull. 2003;26(2):159-164.
• Katanic J et al. Filipendula ulmaria (L.) Maxim. — a review of traditional use, pharmacology, and toxicology. J Ethnopharmacol. 2015;176:367-381.
• Wichtl M. Herbal Drugs and Phytopharmaceuticals: A Handbook for Practice on a Scientific Basis. 3rd ed. CRC Press; 2004.
• Altmeyers Encyclopedia: Filipendulae ulmariae herba entry.

Connections

• Compare salicylate mechanism with Willow Bark (much stronger evidence base; EMA well-established use)
• Compare musculoskeletal indication with Devils Claw (different mechanism; superior clinical evidence)
• Compare anti-inflammatory approach with Boswellia (LOX inhibition rather than COX pathway)
• Compare diaphoretic use with Elderflower and Linden Flower (traditional sweat-cure herbs for colds)